9 results about "Methicillin resistance" patented technology

The invention relates to the field of modern pharmacy of traditional Chinese medicines, and discloses application of leonurine in preparation of antibacterial products. According to the invention, the in-vitro antibacterial activity of leonurine is detected by an agar dilution method and a broth trace dilution method. The result shows that the leonurine can inhibit the proliferation of a staphylococcus aureus standard strain, and also has an inhibiting effect on most of methicillin-sensitive staphylococcus aureus, methicillin-resistant staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus which are obtained by clinical separation; meanwhile, the leonurine can inhibit proliferation of a malassezia standard strain and a clinical isolated strain, also has an inhibiting effect on most of ketoconazole drug-resistant candida and ketoconazole dose dependence-sensitive candida obtained through clinical isolation, and can be used for preparing antibacterial pharmaceutical compositions and skin care products.

Methods of treating preventing and / or substantially reducing a Pseudomonas aeruginosa (PA) infection and / or a Staphylococcus aureus (SA) infection by administration of a bivalent protein subunit-based vaccine are described. The vaccine can protect subjects with a prior history of exposure to SA from a new exposure to PA or SA, including methicillin resistant SA (MRSA), as well as being able to protecting with no prior exposure to a SA infection. Vaccine formulations are also described.

Lipid-based drug delivery vehicles (including liposomal nanoparticles) are described which include antibiotic(s) for the treatment of infections, such as Methicillin-Resistant Staphylococcus (S.) aureus (MRSA) infections and Methicillin-Susceptible S. aureus (MSSA) infections. These drug delivery vehicles have high drug-loading, do not accumulate in the liver, and can optionally include one or more targeting ligands.

The invention provides a methicillin-resistant staphylococcus-derived vesicle and application thereof. The methicillin-resistant staphylococcus-derived vesicle is disclosed. Specifically, the invention provides application of a PBP2a detection reagent in preparation of a diagnostic reagent or a diagnostic kit for diagnosing methicillin-resistant bacterium infection and / or evaluating the treatment effect of methicillin-resistant bacteria. The vesicles provided by the invention carry specific protein markers, such as PBP2a, and the markers can be used for high-sensitivity and specific detection. The method is used for biological research and early diagnosis and treatment.

A method of making a supplemented wound dressing including preparing a coffee extract with or without cardamom and supplementing the wound dressing with the coffee extract is provided. The coffee beans may be Khulani coffee beans and they may be green coffee beans, lightly roasted coffee beans, or medium roasted coffee beans. The supplemented wound dressing prepared according to this method is effective to inhibit bacterial growth, particularly growth of methicillin-resistant Staphylococcus aureus.

The present invention relates to a method for determining the methicillin resistance properties of a strain of Staphylococcus aureus present in a biological sample, comprising the following steps: a) incubation of the biological sample containing said strain of Staphylococcus aureus for at least 15 minutes, in the presence of a beta-lactam antibiotic selected from the following group: cefoxitin and 6-APA (6-aminopenicillanic acid), b) isolation of the bacteria present in said biological sample, c) lysis of the bacteria and hydrolysis of the bacterial proteins, in order to obtain a mixture of peptides, d) analysis of this mixture of peptides by targeted mass spectrometry, the detection of at least one peptide from the PBP2a protein (SEQ ID NO. 1) or PBP2c protein (SEQ ID NO. 2) during this analysis step being indicative of the methicillin resistance of the strain of Staphylococcus aureus present in said biological sample.

The present application relates to the application of Staphylococcus aureus toxin protein related gene SA1833 / SA1832 in treating Staphylococcus aureus infection. Specifically, it relates to the application of Staphylococcus aureus toxin protein related gene SA1833 and / or SA1832 as a target in the preparation of a drug for treating drug-resistant Staphylococcus aureus infection, preferably, the drug resistance is preferably methicillin resistance. With SA1833 and / or SA1832 as a target, the clinical treatment of repeated and persistent infection caused by methicillin-resistant Staphylococcus aureus retention has a significant effect. It provides a new target for the development of drugs for treating repeated infection caused by clinical MRSA strains, provides more choices for the treatment of Staphylococcus aureus, and has a wide application prospect.

The present application belongs to the field of pharmaceutical chemistry and antibacterial drug technology, and particularly relates to a C14 modified pleuromutilin derivative, a preparation method thereof and application thereof in treating gram-positive bacteria, especially gram-positive drug-resistant bacterial infection. The C14 modified pleuromutilin derivative provided by the present application has a structure shown in formula I or formula II. The present application introduces a heterocyclic side chain (4-trifluoromethylphenylthiol or 1-(4,5-dihydrothiazole-2-yl)azetidine-3-thiol) at the C14 site of pleuromutilin to synthesize the C14 modified pleuromutilin derivative, which significantly enhances the antibacterial activity of the C14 modified pleuromutilin derivative on methicillin-resistant Staphylococcus aureus (MRSA) and cfr gram-positive bacterial strains, and has high drug resistance barrier, low cytotoxicity and hemolyticity. The C14 modified pleuromutilin derivative provided by the present application is suitable for treating multiple drug-resistant bacterial infection in veterinary and human medicine. Formula I, formula II.

The photodynamic therapy composition comprises salvianolic acid B and fibrin, and the salvianolic acid B and the fibrin are in weak interaction to form an interlaced or interpenetrating network so as to achieve photodynamic therapy synergism. Photodynamic therapy active components are loaded in an acidic environment provided by salvianolic acid B and fibrin, so that O2 <-> is further converted into hydrogen peroxide (H2O2) and hydroxyl radicals (. OH), the dependence on oxygen is reduced, and the efficiency of the photodynamic therapy is improved. Through verification, the composition disclosed by the invention maintains strong bactericidal activity in resisting infection of methicillin-resistant staphylococcus aureus (MRSA), pseudomonas aeruginosa (Pa) and acinetobacter baumannii (Ab), enhances angiogenesis and collagen deposition, remarkably improves the healing effect, and shows a remarkable treatment advantage in wound management of chronic diabetes mellitus.